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 ORIGINAL ARTICLE 
 Drug treatment in the elderly: An intervention in primary care to 
enhance prescription quality and quality of life 
 INGER NORDIN  OLSSON 1 *  ,  REBECKA  RUNNAMO 1,2  &  PETER  ENGFELDT 1 
 1 Family Medicine Research Centre, School of Health and Medical Sciences,  Ö rebro University Sweden, and  2 Faculty of Health 
Sciences, Link ö ping University, Sweden 
 Abstract 
 Objective. The aim of the study was to assess the effect on prescription quality and quality of life after intervention with 
prescription reviews and promotion of patient participation in primary care.  Design. A randomized controlled study with 
three groups: (A) controls, (B) prescription review sent to physician, and (C) as in B and with a current comprehensive 
medication record sent to the patient.  Setting. The municipality of  Ö rebro, Sweden (130 000 inhabitants).  Intervention. 
The study focused on the easiest possible intervention to increase prescription quality and thereby increase quality of life. 
The intervention should be cost-effi cient, focus on colleague-to-colleague advice, and be possible to perform in the primary 
health care centre without additional resources such as a pharmacist.  Subjects . 150 patients recently discharged from 
hospital. Inclusion criteria were:   75 years,   fi ve drugs and living in ordinary homes.  Main outcome measures. Quality of 
life (EQ-5D index, EQ VAS) and quality of prescriptions.  Results. Extreme polypharmacy was common and persistent in 
all three groups and this was accompanied by an unchanged frequency of drug-risk indicators. There was a low EQ-5D 
index and EQ VAS in all three groups throughout the study. No statistically signifi cant differences were found anywhere 
between the groups.  Conclusion. The intervention seems to have had no effect on quality of prescriptions or quality of life. 
This underlines the major challenge of fi nding new strategies for improving prescription quality to improve patient out-
come measures such as quality of life and reduce the known risks of polypharmacy for the elderly. 
 Key Words:  Frail elderly ,  inappropriate prescribing ,  patient participation ,  polypharmacy ,  quality of life 
 Introduction 
 In the developed world the real challenge for the 
health care system is the ageing population, accom-
panied by an increasing burden of chronic diseases 
and chronic medication [1]. Although modern drugs 
have made great contributions to health and quality 
of life (QoL), increasing proportions of negative side 
effects due to extensive pharmacological treatment 
are observed. Polypharmacy, defi ned as     fi ve drugs 
[2 – 4] is among the most obvious signs of risks in drug 
treatment, resulting in increased risks for inappropri-
ate drug use and adverse drug reactions, followed by 
higher morbidity and hospitalization [5 – 9]. 
 The Swedish National Board of Health and Wel-
fare (SoS) and Swedish Association of Local Author-
ities and Regions (SALAR) concur with the WHO 
recommendations for drug use in the elderly, where 
the indication is the basic principle, followed by ben-
efi ts of treatment in relation to harmfulness and 
inappropriateness [10,11]. The SoS has identifi ed 
some drug-risk indicators in treatment: drugs not 
appropriate for use in the elderly. Occurrence of 
these drugs in the patient ’ s medication list signals 
increased risks of adverse drug reactions and drug 
interactions which could affect the quality of drug 
treatment and the patient ’ s well-being [10]. The most 
obvious goal for health care is to help people live 
longer and feel better [12]. As the burden of chronic 
diseases rises as we live longer, there is a need for 
focusing on  “ well-being ” , that is QoL, as a main out-
come measure [1]. 
 Polypharmacy and/or poor quality of drug treat-
ment are consequently challenges that should be 
addressed. Drug treatment can be either the facilitator, 
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which gives the opportunities, or the opposite, an 
intensifi er of problems by occurrence of unaccept-
able side effects possibly leading to decreased QoL. 
 There are currently no studies that have defi nitively 
determined whether various methods designed to 
reduce drug-related problems in the elderly affect QoL. 
Most studies in the area focus on prescription reviews 
done by drug specialists, for example pharmacists [13]. 
The evidence that this kind of intervention can prevent 
medication-related adverse events is weak [14,15]. In 
this study we wanted to investigate whether a more 
basic kind of intervention and prescription review could 
be effective. We wanted to conduct a study that focused 
on the easiest possible intervention to increase prescrip-
tion quality and thereby increase QoL. The intervention 
should be cost effi cient, focus on colleague to colleague 
advice and possible to perform in the primary health-
care centre without additional resources such as a phar-
macist. The aim of the intervention study was to 
examine whether prescription reviews sent from a pri-
mary care physician to other primary care physicians 
could affect prescription quality and the patient ’ s QoL, 
and also whether there were any additive effects by 
encouraging the patients to question their drug treat-
ment by giving them their medication record. 
 Material and methods 
 During the period September 2006 to May 2007, all 
patients ready for discharge from the University Hos-
pital in  Ö rebro and fulfi lling the criteria were eligible 
for the study. Inclusion criteria were:     75 years,    
fi ve drugs and living in ordinary homes. Exclusion cri-
teria were dementia, abuse, or malignant disease diag-
nosed before the study start. Moving to a nursing home 
during the study also resulted in exclusion. The elec-
tronic care planning system (Meddix), used throughout 
the County Council and municipalities, made the sur-
veillance of all discharges complete and all patients had 
the same opportunity to be included. The study was 
performed in primary care, since family physicians are 
responsible for the medical care of the elderly after dis-
charge from hospital. The patients in the study were 
followed for one year with study end in May 2008. 
 At the time of discharge all patients were regis-
tered in the care planning system and a message was 
sent to the research centre. If the patient was eligible, 
a letter concerning the study including informed 
consent was sent to the patient. A research assistant 
without any connection to the study consecutively 
randomized the patients to one of the three study 
groups (Figure 1): 
 Group A (control): home visit by study nurse  •
within one month after discharge, QoL survey 
by post at six months, and second home visit by 
study nurse at 12 months. 
 Group B (intervention): as group A and a letter  •
with a prescription review (according to points 
1 – 4 below) sent to the physician/primary health 
care centre. 
 Group C (intervention): as group B combined  •
with a current and comprehensive medication 
record consisting of the patient ’ s written drug 
regimen and indications sent to the patient to 
enable participation in his/her drug treatment. 
This was accompanied by an instruction to uti-
lize the record throughout the health care sys-
tem, make notes, and discuss their drug treatment 
with their physicians [11]. 
 During the home visit patients in all three groups were 
asked about their drug regimen and compliance to cap-
ture their  “ true ” medication record. To measure QoL 
the validated questionnaire EQ-5D was used after 
approval of the EuroQol group [16,17]. EQ-5D is a 
generic instrument evaluating function in fi ve dimen-
sions (mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression). The EQ-5D index was 
used for an overall estimation of QoL [18]. EQ VAS 
was used for self-rating of current health-related QoL. 
 The study physician completed a prescription 
review assessing the following as indicators of pre-
scription quality [10,13,19 – 21]: 
1.  number of drugs; total, on regular basis and on 
demand; 
 2.  number of drug-risk indicators (long- and 
short-acting benzodiazepines, sleeping pills, 
NSAIDs, digitalis, diuretics, SSRI, PPI, neuro-
leptics, and drugs with anticholinergic effects); 
 3.  drug interactions by using a computer program 
that warns for interactions of C-type (adjust-
ment of dose recommended) and D-type (avoid-
ance of drug recommended) [22]; 4.number of 
medication errors and/or discrepancies between 
 Today there are no evidence-based models  •
or smart tools for optimizing available 
drug treatment. 
 Prescribing for the elderly is a time-con- •
suming responsibility for physicians in pri-
mary care. 
 A basic colleague-to-colleague interven- •
tion with prescription reviews had no 
effect on quality of prescriptions or quality 
of life. 
 New strategies are needed for improving  •
prescription quality to improve patient 
outcome measures such as quality of life. 
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 Drug treatment in the elderly 5
medication list (prescriptions) and the patient ’ s 
own regime (drugs noted but not taken, drugs 
taken but not noted, and wrong dosages). 
 The prescription reviews were then sent to the pri-
mary health care centres to alert the family physi-
cians together with a letter explaining the errors and 
suggested proceedings. 
 At study end the comprehensive medication 
records for the patients in group C were collected by 
the nurse. All home visits throughout the study were 
done by the same study nurse who was blinded to 
the groups. Before study start all primary health care 
centres and family physicians in the area were 
informed about the study. 
 Statistical analyses 
 There are no data concerning the effect of prescrip-
tion reviews on QoL and therefore we had to 
approximate the effect of such an intervention. We 
estimated that QoL could increase by 20% in the 
intervention groups. With a power of 80% and a sig-
nifi cance level of 5% it was then calculated that a 
total study population of 150 individuals, with 50 
individuals in each arm, should be an appropriate 
sample size taking into account a dropout rate of 
10%. The data were analysed using the SPSS pro-
gram, version 15. 
 Results 
 A total of 150 patients were identifi ed for inclusion 
in the study. The mean ages in groups A, B, and C 
were 82.5    4.9 (mean    SD), 83.4    5.1 and 
83.9    5.1. The sex distributions were 56% / 44% 
(female/male), 63% / 37%, and 64% / 36% respec-
tively. No signifi cant differences between the groups 
were observed in respect of mortality or dropouts 
(for numbers and reasons see Figure 1). 
*see methods 
Fulfilling criteria
Informed consent
Home visit by nurse*
n = 150
Randomization
C (intervention)
Prescription review
Letter to physician
Medication record sent
to patient
n = 50
B (intervention)
Prescription review
Letter to physician
n = 49
Home visit by nurse*
n = 33
Home visit by nurse*
n = 39
EQ-5D and EQ VAS by
post
EQ-5D and EQ VAS by
post
Home visit by nurse* 
n = 33
EQ-5D and EQ VAS by
post
A (control)
Prescription review
n = 48
other reasons = 1other reasons = 2
dead = 7 
nursing home = 3 
other reasons = 5 
dead = 5
nursing home = 1
other reasons = 4
dead = 7
nursing home = 1
other reasons = 9
Study start
6 months
12 months
 
Figure 1. Study fl ow chart. 
Note: Flow chart of the study and randomization process. Dropouts for other reasons include no answer after three telephone calls, not 
opening the door at agreed visiting time, and no longer willing to participate. 
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 Table I shows the prescription quality for the 
patients who completed the study. There were no sig-
nifi cant differences when similar comparisons were 
made with all patients included. Extreme polyphar-
macy (taking   10 drugs) was common and persistent 
in all three groups and this was accompanied by an 
unchanged frequency of drug-risk indicators (Table I). 
The frequency of correct medication lists was very low 
in all three groups (Table I). The frequencies of inter-
actions of types C and D are shown as proportions of 
patients having them (Table I). The 99 prescription 
review letters (49 in group B and 50 in group C) sent 
to physicians/primary care centres, resulted in only 
eight (three and fi ve respectively) actions. 
 For QoL the EQ-5D results are presented as 
recommended by the EuroQol group [17]. The 
 Table I. Prescription quality. 
Group A Group B Group C
Baseline 12 months p-value Baseline 12 months p-value Baseline 12 months p-value
p-value 
overall
Number of drugs per 
patient (median)
8.0 9.0  0.029 10.0 11.0 0.655 10.0 10.0 0.454 0.382
Number of drug-risk 
indicators per patient 
(median)
2.0 2.0 0.181 2.0 2.0 0.813 2.0 2.0 0.401 0.444
Number of medication 
errors per patient 
(median)
5.0 2.0 0.099 3.0 2.0 0.031 3.0 3.0 0.862 0.331
Proportion of correct 
medication lists (%)
10.0 18.0 0.130 4.0 13.0  0.029 8.0 12.0 0.371 0.614
Proportion of patients 
with interactions of 
C type (%)
60.6 57.8 0.135 43.9 48.7 0.327 42.4 48.5 0.705 0.788
Proportion of patients 
with interactions of 
D type (%)
3.0 3.0 0.655 2.6 7.7 0.317 21.2 6.1 0.096 0.088
 Note: For statistical analyses a Wilcoxon, chi-squared, or Kruskal – Wallis test was used. 
 Table II. Frequency distribution (profi le) of the EQ-5D descriptive system for comparison. 1  
Group A Group B Group C
EQ-5D profi le
Baseline
 (n   47)
6 months
 (n   38)
12 months
 (n   34)
Baseline
 (n   49)
6 months
 (n   37)
12 months
 (n   39)
Baseline
 (n   48)
6 months
 (n   35)
12 months
 (n   33)
Mobility:
No problems (%) 13 19 30 14 17 18 8 18 15
Some problems (%) 79 81 64 78 83 74 83 76 76
Confi ned to bed (%) 8 0 6 8 0 8 8 6 9
Self-care:
No problems (%) 62 60 76 67 60 71 62 52 66
Some problems (%) 30 34 12 30 35 24 25 39 22
Unable to (%) 8 6 12 4 5 5 13 9 12
Usual activities:
No problems (%) 45 47 53 47 38 44 44 24 55
Some problems (%) 30 37 32 31 46 36 29 65 21
Unable to (%) 26 16 15 22 16 20 27 12 24
Pain/discomfort:
None (%) 28 5 23 24 16 18 25 11 24
Moderate (%) 53 63 53 51 54 54 62 74 49
Extreme (%) 19 32 24 25 30 28 13 15 27
Anxiety/depression:
None (%) 36 42 56 51 40 37 56 47 42
Moderate (%) 60 47 38 41 57 55 40 53 54
Extreme (%) 4 11 6 8 3 8 4 0 4
 Note:  1 The EQ-5D index varied over time, but there were no statistically signifi cant differences in or between the groups. 
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 Drug treatment in the elderly 7
dimensions mobility, pain/discomfort, and anxiety/
depression show higher percentages with symptoms 
(Table II). The response frequency for the EQ-5D 
questionnaires that were sent to the patients at six 
months was high: 84%, 79% and 80% respectively 
for each group. The EQ-5D index varied over time, 
but there were no signifi cant differences in or between 
the groups (Figure 2). The EQ VAS shows notably 
low scores for the patients ’ own assessment of health-
related QoL (Table III). In group C (patient partici-
pation), the usage of the medication records was 
registered when returned to the research centre. From 
the 33 patients fulfi lling the study at 12 months, 21 
medication records were returned, but only eight of 
them had been used. This was accompanied by dif-
ferent messages listing forgetfulness, feeling unaccus-
tomed to participating, and also referring to fear of 
causing trouble. 
 Discussion 
 The aim of the study was to assess the effect in 
prescription quality and QoL after intervention 
with prescription reviews and promotion of patient 
participation via a randomized controlled study. 
The main results of the study are the persistent low 
values of QoL, demonstrated by low EQ-5D index 
and EQ VAS in all three study groups throughout 
the study. The intervention had no statistically sig-
nifi cant effect on QoL or prescription quality. The 
fi ndings show low interest from the physicians in 
actions for improving prescription quality to achieve 
better QoL by reducing risks for this group of vul-
nerable elderly. The fi ndings also highlight the 
remaining hierarchic structure in health care where 
most of the patients still do not dare to discuss their 
drug treatment. 
 One reason for the physicians ’ unwillingness to 
change prescriptions according to the prescription 
review may be the fact that changes require addi-
tional work, such as increased monitoring and 
follow-up and time to consider the suggestions 
[23]. Another reason is the fact that many pre-
scribers with different specializations are involved 
in the care of the patient, focusing on their area of 
specialization and with no one taking the overall 
responsibility for the patient. All prescribers inde-
pendently of specialization have the same obliga-
tion in the prescribing process [24] but the 
phenomenon of many caregivers/physicians being 
involved causes risks and problems when there is 
no individual caregiver who has an overview of the 
medication list and where the responsibility is not 
apparent [25,26]. 
 Part of the intervention was enablement of patient 
participation in group C. We saw many errors; wrong 
dosages were taken as well as wrong regimens fol-
lowed but the patients did not want to cause prob-
lems in their relationship with the doctor. They 
avoided time-consuming questions, although they 
felt insecure about their medication. The comments 
here were that they  “ wanted information and a good 
relationship ” , accompanied by overall trust in the 
 “ good ” doctors and their judgement on  “ giving the 
right treatment ” , which is similar to fi ndings in other 
studies that address patient participation [27]. This 
reduces discussions concerning the benefi ts and risks 
of polypharmacy, since continuity, as well as access 
and having a  “ good doctor ” , is more important. 
Empowerment of the patient ’ s involvement in his/her 
 
Figure 2. EQ-5D index. 
Note: Statistical analyses were done within and between the 
groups using the Friedman test and Kruskal – Wallis test. No 
signifi cant difference anywhere. 
 Table III. Patients ’ assessments of their own health-related quality of life, EQ VAS. 
Group A Group B Group C
Baseline 6 months 12 months Baseline 6 months 12 months Baseline 6 months 12 months
Mean  EQ VAS score 50 55 56 51 52 54 51 52 56
(  SD) (19) (19) (17) (17) (19) (14) (16) (20) (17)
Median EQ VAS score 50 50 50 50 50 50 50 50 50
(IQR) (40 – 60) (50 – 72) (50 – 68) (45 – 60) (42 – 60) (50 – 60) (40 – 60) (40 – 70) (50 – 64)
 Notes: Statistical analyses were done within and between the groups using the Friedman test and Kruskal – Wallis test. No signifi cant 
difference anywhere. 
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drug treatment is a key issue for the future, and fur-
ther studies will be needed to evaluate the effects on 
treatment quality as well as QoL. 
 The strength of our study is that it was con-
ducted in  “ care as usual ” . The study was com-
pletely randomized and there was no external 
investigators bias since there was only one nurse 
involved who completed all the home visits 
throughout the study. A weakness of our study is 
that our estimation of the effect of the intervention 
on QoL was too high and therefore the power of 
the study is low. This means that there could be a 
small effect on QoL through an intervention like 
ours but such an eventual small effect is probably 
of no clinical signifi cance. 
 Today there are no systematic evidence-based 
models or smart tools for optimizing the drug 
treatment available [6]. This study was planned 
and carried out so that the family physicians 
involved in the intervention had to perform a min-
imum of extra work. The physicians ’ work was 
facilitated by the prescription reviews, which 
showed number of drugs and drug-risk indicators 
as well as warnings of interactions. Interactions of 
C and D type are real risk measurements for the 
patient as well as the health care system, as they 
signal preventable risks in drug treatment [22]. 
The results presented here show low responsive-
ness to the alarm signals. This underlines the major 
challenge of fi nding new strategies for improving 
prescription quality to improve patient outcome 
measures such as QoL and reduce the known risks 
of polypharmacy for the elderly. 
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